Lipid Profile and Atherogenic Risk Assessment in Nigerian Breast Cancer Patients – A Cross-Sectional Study

References

• DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48. doi:10.3322/caac.21412.
   PubMed Web of Science ®Google Scholar
• Azubuike SO, Muirhead C, Hayes L, McNally R. Rising global burden of breast cancer: the case of sub-Saharan Africa (with emphasis on Nigeria) and implications for regional development: a review. World J Surg Oncol. 2018;16(1):63. doi:10.1186/s12957-018-1345-2.
   PubMed Web of Science ®Google Scholar
• Ayoade BA, Agboola AJ, Olatunji AA, Tade AO, Salami BA, Adekoya AO. Clinical characteristics and survival outcome of Breast Cancer in Southwest Nigerian women. J Afr Cancer. 2014;6(2):79–84. doi:10.1007/s12558-014-0311-8.
   Google Scholar
• Afolayan EAO. Cancer in North Western region of Nigeria - an update analysis of Zaria cancer registry data. Western Nig. Jour. of Med. Sci. 2008;1:37–43.
   Google Scholar
• Ogunbiyi JO, Fabowale AO, Ladipo AA, editors. Cancer incidence and top ten cancers in eleven local government areas in Ibadan, Nigeria and its environs, 2004 – 2008. Ibadan M. Alofe (Nig.) Enterprises; 2010. p. 11–17.
   Google Scholar
• Afolayan EAO, Ibrahim OOK, Ayilara GT. Cancer patterns in Ilorin: an analysis of Ilorin Cancer Registry Statistics. Trop J Health Sci. 2012;9:42–7.
   Google Scholar
• Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, et al. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res. 2013;6(9):925–37. doi:10.1158/1940-6207.CAPR-12-0416.
   PubMed Web of Science ®Google Scholar
• Muntoni S, Atzori L, Mereu R, Satta G, Macis MD, Congia M, Tedde A, Desogus A, Muntoni S. Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis. 2009;19(3):218–25. doi:10.1016/j.numecd.2008.06.002.
   PubMed Web of Science ®Google Scholar
• Touvier M, Fassier P, His M, Norat T, Chan DSM, Blacher J, Hercberg S, Galan P, Druesne-Pecollo N, Latino-Martel P, et al. Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Br J Nutr. 2015;114(3):347–57. doi:10.1017/S000711451500183X.
   PubMed Web of Science ®Google Scholar
• Chandler PD, Song Y, Lin J, Zhang S, Sesso HD, Mora S, Giovannucci EL, Rexrode KE, Moorthy MV, Li C, et al. Lipid biomarkers and long-term risk of cancer in the Women’s Health Study. Am J Clin Nutr. 2016;103(6):1397–407. doi:10.3945/ajcn.115.124321.
   PubMed Web of Science ®Google Scholar
• Li X, Liu Z-L, Wu Y-T, Wu H, Dai W, Arshad B, Xu Z, Li H, Wu K-N, Kong L-Q, et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis. 2018;17(1):91. doi:10.1186/s12944-018-0745-1.
   PubMedGoogle Scholar
• Rodrigues Dos Santos C, Fonseca I, Dias S, Mendes de Almeida JC. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer. 2014;14(1):132. doi:10.1186/1471-2407-14-132.
   PubMedGoogle Scholar
• Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, Manjer J, Melander O. Apolipoproteins, lipids and risk of cancer. Int J Cancer. 2016;138(11):2648–56. doi:10.1002/ijc.30013.
   PubMed Web of Science ®Google Scholar
• Llanos AA, Makambi KH, Tucker CA, Wallington SF, Shields PG, Adams-Campbell LL. Cholesterol, lipoproteins, and breast cancer risk in African American women. Ethn Dis. 2012;22(3):281–7.
   PubMed Web of Science ®Google Scholar
• His M, Zelek L, Deschasaux M, Pouchieu C, Kesse-Guyot E, Hercberg S, Galan P, Latino-Martel P, Blacher J, Touvier M, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol. 2014;29(2):119–32. doi:10.1007/s10654-014-9884-5.
   PubMed Web of Science ®Google Scholar
• Nowak C, Ärnlöv J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk. Nat Commun. 2018;9(1):3957. doi:10.1038/s41467-018-06467-9.
   PubMed Web of Science ®Google Scholar
• Carter PR, Uppal H, Chandran KR, Bainei KR, Potluri R. Patients with a diagnosis of hyperlipidaemia have a reduced risk of developing breast cancer and lower mortality rates: a large retrospective longitudinal cohort study from the UK ACALM registry. Eur Heart J. 2017;38(Suppl 1):644.
   Google Scholar
• Kitahara CM, Berrington de González A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592–8. doi:10.1200/JCO.2010.31.5200.
   PubMed Web of Science ®Google Scholar
• Gernaat SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, van der Pol CC, Bijlsma RM, Grobbee DE, Verkooijen HM, Peeters PH. The risk of cardiovascular disease following breast cancer by Framingham risk score. Breast Cancer Res Treat. 2018;170(1):119–27. doi:10.1007/s10549-018-4723-0.
   PubMed Web of Science ®Google Scholar
• Rehammar JC, Jensen M-B, McGale P, Lorenzen EL, Taylor C, Darby SC, Videbæk L, Wang Z, Ewertz M. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. Radiother Oncol. 2017;123(2):299–305. doi:10.1016/j.radonc.2017.03.012.
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222–8. doi:10.1200/JCO.2013.48.7884.
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.
   PubMed Web of Science ®Google Scholar
• Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85(1):37–45. doi:10.1161/01.cir.85.1.37.
   PubMed Web of Science ®Google Scholar
• Kannel WB. Risk stratification of dyslipidemia: insights from the Framingham Study. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(3):187–93. doi:10.2174/1568016054368250.
   PubMedGoogle Scholar
• Dai D, Chen B, Wang B, Tang H, Li X, Zhao Z, Li X, Xie X, Wei W. Pretreatment TG/HDL-C ratio is superior to triacylglycerol level as an independent prognostic factor for the survival of triple negative breast cancer patients. J Cancer. 2016;7(12):1747–54. doi:10.7150/jca.15776.
   PubMed Web of Science ®Google Scholar
• Akinbami A, Popoola A, Adediran A, Dosunmu A, Oshinaike O, Adebola P, et al. Full blood count pattern of pre-chemotherapy breast cancer. Caspian J Intern Med. 2013;4(1):574–9.
   PubMedGoogle Scholar
• Owiredu KBA, Donkor S, Addai BW, Amidu N. Serum lipid profile of breast cancer patients. Pak J Biol Sci. 2009;12(4):332–8. doi:10.3923/pjbs.2009.332.338.
   PubMedGoogle Scholar
• Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017;18(8):e457–71–e471. doi:10.1016/S1470-2045(17)30411-4.
   Web of Science ®Google Scholar
• Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, O’Brien KM, Adami H-O, Baglietto L, Bernstein L, Bertrand KA, et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 2018;4(11):e18177. doi:10.1001/jamaoncol.2018.1771.
   Web of Science ®Google Scholar
• Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen progestin use and hormone receptor status. Epidemiol Rev. 2014;36(1):114–36. doi:10.1093/epirev/mxt010.
   PubMed Web of Science ®Google Scholar
• Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63. doi:10.1093/jnci/djq526.
   PubMed Web of Science ®Google Scholar
• Shieh Y, Scott CG, Jensen MR, Norman AD, Bertrand KA, Pankratz VS, Brandt KR, Visscher DW, Shepherd JA, Tamimi RM, et al. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Breast Cancer Res. 2019;21(1):48. doi:10.1186/s13058-019-1129-9.
   PubMedGoogle Scholar
• Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, Ochs-Balcom HM, Thomson CA, Caan BJ, Tinker LF, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the Women’s Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015;1(5):611–21. doi:10.1001/jamaoncol.2015.1546.
   PubMed Web of Science ®Google Scholar
• Nagrani R, Mhatre S, Rajaraman P, Soerjomataram I, Boffetta P, Gupta S, Parmar V, Badwe R, Dikshit R. Central obesity increases risk of breast cancer irrespective of menopausal and hormonal receptor status in women of South Asian Ethnicity. Eur J Cancer. 2016;66:153–61. doi:10.1016/j.ejca.2016.07.022.
   PubMed Web of Science ®Google Scholar
• Ikeoluwapo A, Adetola O, Adenike A-S, Olushola M, Modupe L, Abideen O, Nathaniel A, Millicent O. Pattern of breast cancer risk factors among pre and post-menopausal women at a Primary Care Clinic in Nigeria. Trop J Obstet Gynaecol. 2016;33(2):220–7. doi:10.4103/0189-5117.192232.
   Google Scholar
• Olatunji T, Sowunmi A, Ketiku K, Campbell O. Sociodemographic correlates and management of breast cancer in radiotherapy department, Lagos University Teaching Hospital; A ten year review. J Clin Sci. 2019;16(4):111–9. doi:10.4103/jcls.jcls_82_18.
   Google Scholar
• Odutola MK, Olukomogbon T, Igbinoba F, Otu TI, Ezeome E, Hassan R, Jedy-Agba E, Adebamowo SN. Cancers attributable to overweight and obesity from 2012 to 2014 in Nigeria: a population-based cancer registry study. Front Oncol. 2019;9:460. doi:10.3389/fonc.2019.00460.
   PubMed Web of Science ®Google Scholar
• Pereira A, Garmendia ML, Alvarado ME, Albala C. Hypertension and the risk of breast cancer in chilean women: a case-control study. Asian Pac J Cancer Prev. 2012;13(11):5829–34. doi:10.7314/apjcp.2012.13.11.5829.
   PubMedGoogle Scholar
• Radišauskas R, Kuzmickienė I, Milinavičienė E, Everatt R. Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. Medicina. 2016;52(2):89–98. doi:10.1016/j.medici.2016.03.002.
   PubMedGoogle Scholar
• Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–57. doi:10.1038/nrurol.2010.46.
   PubMed Web of Science ®Google Scholar
• Seretis A, Cividini S, Markozannes G, Tseretopoulou X, Lopez DS, Ntzani EE, Tsilidis KK. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. 2019;9(1):8565. doi:10.1038/s41598-019-45014-4.
   PubMedGoogle Scholar
• Wu Y-T, Luo Q-Q, Li X, Arshad B, Xu Z, Ran L, Zhao C-X, Wu H, Shi Y-L, Chen H-R, et al. Clinical study on the prevalence and comparative analysis of metabolic syndrome and its components among Chinese breast cancer women and control population. J Cancer. 2018;9(3):548–55. doi:10.7150/jca.22968.
   PubMed Web of Science ®Google Scholar
• Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, He J. Hypertension and breast cancer risk: a systematic review and metaanalysis. Sci Rep. 2017;7(1):44877. doi:10.1038/srep44877.
   PubMedGoogle Scholar
• Akinyemiju T, Salako O, Daramola A, Alatise O, Adeniyi A, Ogun G, Ayandipo O, Olajide T, Olasehinde O, Arowolo O, et al. Collaborative molecular epidemiology study of metabolic dysregulation, DNA methylation, and breast cancer risk among Nigerian women: MEND Study objectives and design. J Glob Oncol. 2019;5:1–9. doi:10.1200/JGO.18.00226.
   PubMed Web of Science ®Google Scholar
• Olaniyan MF, Seun BC. Lipid profile and hormone sensitive lipase [HSL] gene variant in nigeria women with breast cancer. Int J Allied Med Sci Clin Res. 2016;4(3):507–16.
   Google Scholar
• Ghahremanfard F, Mirmohammadkhani M, Shahnazari B, Gholami G, Mehdizadeh J. The valuable role of measuring serum lipid profile in cancer progression. Oman Med J. 2015;30(5):353–7. doi:10.5001/omj.2015.71.
   PubMedGoogle Scholar
• His M, Dartois L, Fagherazzi G, Boutten A, Dupré T, Mesrine S, Boutron-Ruault M-C, Clavel-Chapelon F, Dossus L. Associations between serum lipids and breast cancer incidence and survival in the E3N prospective cohort study. Cancer Causes Control. 2017;28(1):77–88. doi:10.1007/s10552-016-0832-4.
   PubMed Web of Science ®Google Scholar
• Kökoğlu E, Karaarslan I, Karaarslan HM, Baloğlu H. Alterations of serum lipids and lipoprotein in breast cancer. Cancer Lett. 1994;82(2):175–8. doi:10.1016/0304-3835(94)90008-6.
   PubMed Web of Science ®Google Scholar
• Carter PR, McGowan J, Uppal H, Chandran S, Sarma J, Potluri R. Hyperlipidemia reduces mortality in breast, prostate, lung and bowel cancer. Heart. 2016;102(Suppl 6):A57–A58. doi:10.1136/heartjnl-2016-309890.79.
   PubMedGoogle Scholar
• Casaburi I, Chimento A, De Luca A, Nocito M, Sculco S, Avena P, Trotta F, Rago V, Sirianni R, Pezzi V. Cholesterol as an endogenous ERRα agonist: a new perspective to cancer treatment. Front Endocrinol. 2018;9:525. doi:10.3389/fendo.2018.00525.
   PubMed Web of Science ®Google Scholar
• Garcia-Estevez L, Moreno-Bueno G. Updating the role of obesity and cholesterol in breast cancer. Breast Cancer Res. 2019;21(1):35. doi:10.1186/s13058-019-1124-1.
   PubMed Web of Science ®Google Scholar
• Reddy VA, Killampalli LK, Prakash AR, Naag S, Sreenath G, Biraggari SK. Analysis of lipid profile in cancer patients, smokers and non smokers. Dent Res J. 2016;13(6):494–9. doi:10.4103/1735-3327.197036.
   PubMedGoogle Scholar
• Mishra S. Lipid profile in breast cancer patients. Int J Pharm Med Res. 2015;3(1):29–36.
   Google Scholar
• Olamoyegun MA, Oluyombo R, Asaolu SO. Evaluation of dyslipidaemia, lipid ratio and atherogenic index as cardiovascular risk factors among semi- urban dwellers in Nigeria. Ann Afr Med. 2016;15(4):194–9. doi:10.4103/1596-3519.194280.
   PubMed Web of Science ®Google Scholar
• Laisupasin P, Thompat W, Sukarayodhin S, Sornprom A, Sudjaroen Y. Comparison of serum lipid profiles between normal controls and breast cancer patients. J Lab Physicians. 2013;5(1):38–41. doi:10.4103/0974-2727.115934.
   PubMedGoogle Scholar
• Abdelsalam KEA, Hassan IK, Sadig IA. The role of developing breast cancer in alteration of serum lipid profile. J Res Med Sci. 2012;17(6):562–5.
   PubMed Web of Science ®Google Scholar
• Koleva DI, Andreeva-Gateva PA, Orbetzova MM, Atanassova IB, Nikolova J. Atherogenic index of plasma, Castelli risk indexes and leptin/adiponectin ratio in women with metabolic syndrome. Int J Pharm Med Res. 2015;3(5):12–8.
   Google Scholar
• Cedó L, Reddy ST, Mato E, Blanco-Vaca F, Escolà-Gil JC. HDL and LDL: potential new players in breast cancer development. J Clin Med. 2019;8(6):853. doi:10.3390/jcm8060853.
   PubMed Web of Science ®Google Scholar
• Lofterød T, Mortensen ES, Nalwoga H, Wilsgaard T, Frydenberg H, Risberg T, Eggen AE, McTiernan A, Aziz S, Wist EA, et al. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes. BMC Cancer. 2018;18(1):654. doi:10.1186/s12885-018-4568-2.
   PubMed Web of Science ®Google Scholar
• Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, Vogelman JH, Orentreich N. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev. 1998;7(6):483–8.
   PubMed Web of Science ®Google Scholar
• Angius F, Spolitu S, Uda S, Deligia S, Frau A, Banni S, Collu M, Accossu S, Madeddu C, Serpe R, et al. High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts. Sci Rep. 2015;5(1):17812. doi:10.1038/srep17812.
   PubMedGoogle Scholar
• Grewal T, de Diego I, Kirchhoff MF, Tebar F, Heeren J, Rinninger F, Enrich C. High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J Biol Chem. 2003;278(19):16478–81. doi:10.1074/jbc.C300085200.
   PubMed Web of Science ®Google Scholar
• Pussinen PJ, Karten B, Wintersperger A, Reicher H, McLean M, Malle E, Sattler W. The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1(CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem J. 2000;349(Pt 2):559–66. doi:10.1042/0264-6021:3490559.
   PubMedGoogle Scholar
• Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, Niimi M, Miyauchi A, Wong NCW, Ishida T. mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004;64(4):1515–21. doi:10.1158/0008-5472.can-03-0675.
   PubMed Web of Science ®Google Scholar
• Yuan B, Wu C, Wang X, Wang D, Liu H, Guo L, Li X-A, Han J, Feng H. High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer. Tumour Biol. 2016;37(3):3581–8. doi:10.1007/s13277-015-4141-4.
   PubMedGoogle Scholar
• Kaji H. High-density lipoproteins and the immune system. J Lipids. 2013;2013:684903–8. doi:10.1155/2013/684903.
   PubMedGoogle Scholar
• Luigi Catapano A, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity. Cardiovasc Res. 2014;103(3):372–83. doi:10.1093/cvr/cvu150.
   PubMed Web of Science ®Google Scholar
• Bielecka-Dąbrowa A, Hannam S, Rysz J, Banach M. Malignancy-associated dyslipidemia. Open Cardiovasc Med J. 2011;5:35–40. doi:10.2174/1874192401105010035.
   PubMedGoogle Scholar
• Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat. 2003;79(1):11–6. doi:10.1023/a:1023348021773.
   PubMed Web of Science ®Google Scholar
• Tian W, Yao Y, Fan G, Zhou Y, Wu M, Xu D, Deng Y. Changes in lipid profiles during and after (neo)adjuvant chemotherapy in women with early-stage breast cancer: a retrospective study. PLoS One. 2019;14(8):e0221866. doi:10.1371/journal.pone.0221866.
   PubMed Web of Science ®Google Scholar
• Arpino G, De Angelis C, Buono G, Colao A, Giuliano M, Malgieri S, Cicala S, De Laurentiis M, Accurso A, Crispo A, et al. Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy. Breast Cancer Res Treat. 2015;154(1):127–32. doi:10.1007/s10549-015-3586-x.
   PubMed Web of Science ®Google Scholar
• Rzymowska J. Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients. Pathobiology. 1999;67(3):129–32. doi:10.1159/000028062.
   PubMed Web of Science ®Google Scholar
• Yıldız A, Seçen Ö, Yıldız C, Çiçekçi M. Relationship between breast arterial calcification and lipid profile, plasma atherogenic index, Castelli’s risk index and atherogenic coefficient in premenopausal women. IJC Metabolic & Endocrine. 2016;11:19–22. doi:10.1016/j.ijcme.2016.05.003.
   Google Scholar
• Sousa-e-Silva ÉPd, Conde DM, Costa-Paiva L, Martinez EZ, Pinto-Neto AM. Cardiovascular risk in middle-aged breast cancer survivors: a comparison between two risk models. Rev Bras Ginecol Obstet. 2014;36(4):157–62. doi:10.1590/S0100-720320140050.0002.
   PubMedGoogle Scholar
• Law W, Johnson C, Rushton M, Dent S. The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population. Curr Oncol. 2017;24(5):e348–e353. doi:10.3747/co.24.3684.
   PubMed Web of Science ®Google Scholar
• So JH, Lee JK, Shin JY, Park W. Risk of cardiovascular disease using Framingham Risk Score in Korean cancer survivors. Korean J Fam Med. 2016;37(4):235–41. doi:10.4082/kjfm.2016.37.4.235.
   PubMedGoogle Scholar
• Poullis M, McShane J, Shaw M, Page R, Shackcloth M, Mediratta N. Framingham risk–based survival of non-small-cell lung cancer. Asian Cardiovasc Thorac Ann. 2012;20(1):30–5. doi:10.1177/0218492311432801.
   PubMedGoogle Scholar
• Osegbe ID, Dada A, Soriyan O. Framingham risk assessment of metabolic syndrome patients at a tertiary hospital in Nigeria. Afr J Med Health Sci. 2017;16(2):89– 93. doi:10.4103/ajmhs.ajmhs_35_17.
   Google Scholar
• Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–e66. doi:10.1161/CIR.0000000000000556.
   PubMed Web of Science ®Google Scholar
• Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6–13. doi:10.1097/EDE.0000000000000394.
   PubMed Web of Science ®Google Scholar
• Gernaat SAM, Ho PJ, Rijnberg N. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;26: s 49.
   Google Scholar
• Riihimäki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. Death causes in breast cancer patients. Ann Oncol. 2012;23(3):604–10. doi:10.1093/annonc/mdr160.
   PubMed Web of Science ®Google Scholar
• Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472. doi:10.1161/JAHA.113.000472.
   PubMed Web of Science ®Google Scholar